glp 1 clinical trials recruiting GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Current Insights, Advantages and Challenges

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained considerable attention in recent years as promising therapeutic agents for MASLD, particularly owing to their well-established efficacy in treating type 2 diabetes mellitus (T2DM) and obesity, conditions closely implicated to MASLD pathogenesis (2, 5)

Most of that added risk traced back to a specific, usually temporary kind of shedding called telogen effluvium, where physical or metabolic stress pushes hair into a resting phase and it falls out more than usual

Interested in Hyperthyroidism Treatment

In these situations, patients may have high B12 on blood work but still exhibit neurological symptoms of deficiency (tingling, numbness, cognitive changes)

Khan AA, Alsahli MA, Rahmani AH